GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Days Sales Outstanding

Ipsen (IPSEY) Days Sales Outstanding : 69.20 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Ipsen Days Sales Outstanding?

Ipsen's average Accounts Receivable for the six months ended in Dec. 2023 was $696 Mil. Ipsen's Revenue for the six months ended in Dec. 2023 was $1,836 Mil. Hence, Ipsen's Days Sales Outstanding for the six months ended in Dec. 2023 was 69.20.

The historical rank and industry rank for Ipsen's Days Sales Outstanding or its related term are showing as below:

IPSEY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.57   Med: 69.72   Max: 73.66
Current: 70.4

During the past 13 years, Ipsen's highest Days Sales Outstanding was 73.66. The lowest was 66.57. And the median was 69.72.

IPSEY's Days Sales Outstanding is ranked better than
51.35% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs IPSEY: 70.40

Ipsen's Days Sales Outstanding increased from Dec. 2022 (69.04) to Dec. 2023 (69.20).

Ipsen Days Sales Outstanding Historical Data

The historical data trend for Ipsen's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Days Sales Outstanding Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.42 67.41 71.51 71.37 68.76

Ipsen Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.61 74.75 69.04 71.28 69.20

Competitive Comparison of Ipsen's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Ipsen's Days Sales Outstanding falls into.


Ipsen Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Ipsen's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (670.021 + 688.441) / 2 ) / 3605.671*365
=679.231 / 3605.671*365
=68.76

Ipsen's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (703.575 + 688.441) / 2 ) / 1835.66*365 / 2
=696.008 / 1835.66*365 / 2
=69.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen  (OTCPK:IPSEY) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Ipsen Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Ipsen's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (IPSEY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (OTCPK:IPSEY) » Definitions » Days Sales Outstanding
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523
Traded in Other Exchanges
IPSEF:USA 0MH6:UK IPN:France I7G:Germany
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.